Michael Koenigsmann
Overview
Explore the profile of Michael Koenigsmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kutsch N, Giza A, Robrecht S, Stumpf J, Federhen A, Stoltefuss A, et al.
Eur J Haematol
. 2024 May;
113(2):235-241.
PMID: 38693677
Long-term data of chronic lymphocytic leukemia (CLL) patients with favorable risk who were treated with fludarabine, cyclophosphamide, and rituximab (FCR) within clinical trials show good efficacy. We here report long-term...
2.
Schulz F, Hauch U, Ketzler-Henkel S, von der Heyde E, Koenigsmann M, Lauseker M, et al.
J Clin Med
. 2023 Oct;
12(20).
PMID: 37892707
Myelodysplastic syndromes and myeloproliferative neoplasms both represent hematologic diseases associated with bone marrow failure often resulting in anemia. For those patients, transfusion of red blood cell (RBC) units is essential...
3.
Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Reiser M, et al.
Ann Hematol
. 2023 Oct;
102(12):3383-3399.
PMID: 37792065
Ruxolitinib (RUX) is a Janus kinase 1/2 inhibitor (JAKi) approved in the EU for treating disease‑related splenomegaly or symptoms in adults patients with myelofibrosis (MF). This is an interim analysis...
4.
Furstenau M, Giza A, Stumpf T, Robrecht S, Maurer C, Linde H, et al.
Am J Hematol
. 2021 Sep;
96(12):E457-E460.
PMID: 34591989
No abstract available.
5.
Knauf W, Abenhardt W, Koenigsmann M, Maintz C, Sandner R, Zahn M, et al.
Hematol Oncol
. 2021 May;
39(3):313-325.
PMID: 33942348
Owing to its heterogeneity and rarity, management of disseminated marginal zone B-cell lymphoma (MZL) remains largely understudied. We present prospective data on choice of systemic treatment and survival of patients...
6.
Al-Batran S, Hofheinz R, Reichart A, Pauligk C, Schonherr C, Schlag R, et al.
Int J Cancer
. 2020 Oct;
148(6):1478-1488.
PMID: 33038277
Few data exist on health-related quality of life (QoL) in patients with metastatic pancreatic cancer (mPC) receiving first-line chemotherapy (Awad L ZE, Mesbah M Boston, MA. Applying survival data methodology...
7.
Weide R, Schnell R, Schardt C, Koenigsmann M, Otremba B, Zahn M, et al.
BMC Immunol
. 2020 Jul;
21(1):39.
PMID: 32600256
Background: The effects of intravenous immunoglobulin G replacement on perceived health and infection susceptibility of patients suffering from immunoglobulin G (IgG) deficiencies should be evaluated in a prospective analysis. Methods:...
8.
Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, et al.
Lancet
. 2019 Apr;
393(10184):1948-1957.
PMID: 30982686
Background: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and...
9.
Reiser M, Dorfel S, Hensel M, Hoesl M, Jordan W, Koenigsmann M, et al.
Eur J Haematol
. 2018 Feb;
100(5):455-464.
PMID: 29393986
Objectives: This study was conducted to investigate the real-world effectiveness and tolerability of rituximab-containing chemoimmunotherapies, which have become the standard of care for chronic lymphocytic leukaemia (CLL), particularly for physically...
10.
Al-Batran S, Homann N, Pauligk C, Illerhaus G, Martens U, Stoehlmacher J, et al.
JAMA Oncol
. 2017 Apr;
3(9):1237-1244.
PMID: 28448662
Importance: Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. Objective: To evaluate outcome in patients with limited metastatic disease who receive...